Alligator Bioscience AB
STO:ATORX

Watchlist Manager
Alligator Bioscience AB Logo
Alligator Bioscience AB
STO:ATORX
Watchlist
Price: 6.383 SEK 5.02%
Market Cap: 197.2m SEK

Operating Margin
Alligator Bioscience AB

-419.7%
Current
-570%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-419.7%
=
Operating Profit
-213.2m
/
Revenue
50.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Alligator Bioscience AB
STO:ATORX
197.2m SEK
-420%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.2B USD
30%
US
Amgen Inc
NASDAQ:AMGN
159.7B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
138.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
118.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.3B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.4B USD
-5%

Alligator Bioscience AB
Glance View

Market Cap
197.2m SEK
Industry
Biotechnology

Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.

ATORX Intrinsic Value
15.329 SEK
Undervaluation 58%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-419.7%
=
Operating Profit
-213.2m
/
Revenue
50.8m
What is the Operating Margin of Alligator Bioscience AB?

Based on Alligator Bioscience AB's most recent financial statements, the company has Operating Margin of -419.7%.

Back to Top